21 Oct ACG 2022 Annual Scientific Meeting, Charlotte, North Carolina

Search
Close this search box.
ASX:RHT

Iron Monitoring in Cancer Survivors – Clinician Survey

9 September, 2016

Iron Overload is increasingly recognised as a possible complication for cancer survivors who have received multiple blood transfusions during their cancer treatment. FerriScan can reliably and accurately screen for Iron Overload in cancer survivors with a history of blood transfusions, overcoming the poor sensitivity and specificity of serum ferritin and avoiding reliance on transfusion records, which can be incomplete.

We are asking for clinicians treating cancer survivors to help us find out more about current practice in iron monitoring and management  by taking the survey. The survey takes only 3 minutes and anonymised results will be published on our website.

To show our appreciation, all clinicians responding to the survey will receive a $9.99 USD Amazon voucher.

To complete the survey please click here…

For further information on the benefits of using FerriScan to monitor iron overload in cancer survivors please refer to our fact sheet by clicking here…